Tivozanib’s Efficacy Behind Checkpoint Inhibitors In Renal Cell Carcinoma Reassured US FDA

 
• By Sue Sutter
  
Foosball
Tivozanib demonstrated efficacy when used third-line behind a checkpoint inhibitor. • Source: Alamy

More from Drug Review Profiles

More from Product Reviews